Acustop Cataplasma

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acustop Cataplasma

Property Description
Active ingredient Flurbiprofen
Form Cataplasma (Soft, adhesive transdermal patch)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Localized relief of pain and inflammation
Origin Synthetic (Propionic acid derivative)

Composition and Classification: The Flurbiprofen NSAID Identity

Acustop Cataplasma is a topical medicine whose primary component is the active ingredient flurbiprofen, a synthetic compound derived from propionic acid. Flurbiprofen is globally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This pharmacological classification indicates that the medicine functions by producing an anti-inflammatory and analgesic effect, primarily through the inhibition of the synthesis of prostaglandins, which are responsible for pain and inflammation signaling. The specific formulation is clinically recognized for its ability to deliver the therapeutic agent directly into the skin to target localized symptoms.

Understanding the Cataplasma Dosage Form and Delivery

The medicine is formulated as a cataplasma, a specialized type of soft, adhesive transdermal patch or plaster. This dosage form allows the medication to be applied directly to the skin, where it functions as a Transdermal Drug Delivery System (TDDS). The cataplasma typically consists of a flexible hydrogel matrix containing the flurbiprofen, supported by a nonwoven fabric, enabling gradual release and percutaneous absorption of the active compound. The design facilitates the concentration of the therapeutic agent in the underlying local tissues rather than relying on high levels of systemic circulation, providing a focused method for managing localized pain.

General Therapeutic Purpose of Flurbiprofen Cataplasma

The overarching purpose of Acustop Cataplasma is to provide targeted, localized management for discomfort and swelling associated with inflammatory processes. By applying the Flurbiprofen directly via the cataplasma, the medicine delivers a focused anti-inflammatory and analgesic effect. Topical NSAID patches, such as this one, aim to reach therapeutic concentrations at the site of inflammation while minimizing the systemic exposure associated with oral NSAIDs. This mechanism is generally utilized to effectively alleviate symptoms of pain and swelling arising in peripheral structures, such as muscles and joints, offering relief from inflammation in soft tissues.

Regulatory References

  1. NIH: Flurbiprofen - LiverTox

What side effects are possible with Acustop Cataplasma?

Possible Side Effects and Safety Information

Acustop Cataplasma, which delivers the Nonsteroidal Anti-inflammatory Drug (NSAID) flurbiprofen through a transdermal patch, has an official safety profile primarily characterized by localized application site reactions.

Frequency Classification of Adverse Reactions

The most frequent effects are generally confined to the area of application, based on regulatory documentation:

  • Common (may affect up to 1 in 10 people): Application site pruritus (itching) and erythema (redness).
  • Uncommon (may affect up to 1 in 100 people): Localized rash, dermatitis, and paresthesia (tingling or prickling sensation).

Systemic and Serious Safety Considerations

While the topical delivery minimizes systemic exposure, the regulatory label formally documents the potential for rare, class-wide NSAID effects under the Immune System Disorders and Respiratory Disorders categories. These include the documented risk of severe Hypersensitivity Reactions, such as Anaphylaxis and Angioedema, which are considered Serious Adverse Reactions. Gastrointestinal Ulceration and Bleeding is also noted as a safety risk associated with the NSAID pharmacological class.


Population-Specific Constraints and Restrictions

Safety constraints and limitations are explicitly noted in official labeling:

  • Pregnancy: The use of the patch is contraindicated during the third trimester of pregnancy, a mandatory safety restriction for all NSAID medicines.
  • Skin Integrity: The patch must not be applied to damaged, broken, or diseased skin, or near mucous membranes or the eyes.
  • Duration: Prolonged use of the patch is associated with an increased risk of developing localized sensitization and hypersensitivity reactions at the application site.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Acustop Cataplasma

Overdose scope

Feature Official Regulatory Information
Documented overdose presentations: Symptoms of acute diclofenac overdose can include lethargy, nausea, vomiting, epigastric pain, and gastrointestinal bleeding.
Physiological systems affected (as stated in label): Gastrointestinal system (bleeding, ulceration), Cardiovascular system (myocardial infarction, stroke risk), Renal system (acute kidney failure).
Dose-related or exposure-related factors (if applicable): Overdose is typically associated with ingestion of the drug or excessive topical exposure leading to high systemic absorption.
Population-specific overdose notes (if applicable): The elderly and patients with pre-existing conditions (e.g., cardiovascular disease, kidney impairment) are at a greater risk for serious adverse events.
Emergency-response statements (as written in official documents): Management is supportive and symptomatic; there is no specific antidote. Contact a certified Poison Control Center immediately.
When immediate medical help is required (label-derived phrasing only): Immediate medical help is required for symptoms such as chest pain, sudden weakness on one side of the body, slurred speech, shortness of breath, vomiting blood, or black/tarry stools.

Overdose classifications (high-level)

Classification Official Regulatory Information
Severity classification (as defined in official documents): Serious adverse events (e.g., GI bleeding, stroke, myocardial infarction) can be fatal.
Regulatory basis (EMA / FDA / etc.): Information is based on regulatory warnings and labeling for topical diclofenac (an NSAID).
Overdose-context constraints (as defined in official documents): Systemic risks of diclofenac must be considered, particularly concerning cardiovascular and gastrointestinal events.

Resulting overdose structure

Official overdose statements:

  • Overdose presentations may include epigastric pain, nausea, vomiting, lethargy, and gastrointestinal bleeding due to the systemic absorption of diclofenac.
  • Serious adverse events such as cardiovascular thrombotic events (myocardial infarction, stroke), severe gastrointestinal ulceration, or acute renal failure can occur without warning.
  • Urgent medical attention is required for sudden symptoms including chest pain, difficulty breathing, weakness on one side of the body, slurred speech, or signs of internal bleeding (e.g., black or bloody stools, vomiting blood).

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile of this product through the known systemic risks of its active NSAID ingredient, diclofenac. While topical application minimizes systemic exposure, an overdose—typically from ingestion or excessive use—can manifest as serious cardiovascular, renal, or gastrointestinal toxicity. Emergency-seeking conditions are directly linked to these severe, potentially fatal adverse events, requiring immediate supportive medical management.

Therapeutic Uses of Acustop Cataplasma

This medication is commonly used in situations involving localized discomfort and symptoms related to inflammatory or irritative states. For specific therapeutic areas of use, the patch is relevant when supportive symptom management is appropriate in clinical settings that involve acute or unstable symptom patterns affecting specific tissues.

Targeted Relief for Acute Musculoskeletal Injuries

This medication is commonly used to help with symptoms that appear suddenly or intensify over time, such as those related to acute soft tissue trauma, including strains, sprains, and contusions. It supports addressing the onset of localized discomfort and visible swelling that commonly accompany these conditions, offering supportive relief during periods when symptoms create noticeable interference with daily activity.

Easing Symptoms of Tendon and Joint Inflammation

The treatment is relevant across conditions involving episodic or fluctuating manifestations in specific body areas. It is applied to help manage pronounced symptoms of regional tenderness, which helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Localized Discomfort

Acustop Cataplasma is commonly used when symptoms related to physical discomfort and swelling create noticeable functional strain, such as restricted movement or stiffness in the affected area. It provides support that helps ease the overall symptom burden, which may help patients cope more steadily with symptom fluctuations where movement is compromised.

Regulatory References

  1. NIH DailyMed drug label for flurbiprofen patch

Eligibility and Restrictions for Use

The eligibility for Acustop Cataplasma, which contains the NSAID flurbiprofen, is strictly defined by regulatory guidelines to prevent the use in certain high-risk populations. The medicine is generally established for use in adults and adolescents (12 years and older).

Populations Who Cannot Use the Medicine (Contraindications)

Use is absolutely contraindicated (must not be used) in patients who meet any of the following criteria:

  • A history of allergic reactions (such as asthma, angioedema, or hives) after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • During the third trimester of pregnancy (typically from 20 to 30 weeks gestation onward).
  • For the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Patients with active or a history of recurrent peptic ulcer/haemorrhage.
  • Patients with severe heart failure, severe renal failure, or severe hepatic failure.

Age and Condition-Based Restrictions

  • Children under 12 years of age are not recommended to use the medicine as its safety and efficacy have not been established by regulators.
  • Older adults must use the medicine with caution due to a documented increased risk of NSAID-related adverse reactions.
  • Use during the first and second trimesters of pregnancy and during lactation/breastfeeding is generally not recommended.

What should I know about interactions with other medicines?

Interaction Scope: Official Regulatory Information

The interaction profile for Acustop Cataplasma is structured around the documented systemic effects of its active substance, Flurbiprofen, an NSAID. The regulatory documentation identifies specific product categories that carry a risk of pharmacokinetic or pharmacodynamic interactions.

Category Documented Interacting Substances
Exposure-Modifying Drugs Coumarin Anticoagulants (e.g., Warfarin), Methotrexate, Lithium, CYP2C9 Inhibitors (e.g., Fluconazole)
Pharmacodynamic Risk Agents Corticosteroids (e.g., Methylprednisolone), Loop and Thiazide Diuretics (e.g., Furosemide)

Interaction Restrictions and Cautions

  • Co-Administration Restriction: Official documentation advises that co-administration with other systemic anti-inflammatory agents should be avoided due to the potential for additive adverse effects.
  • Metabolic Basis: Flurbiprofen is metabolized by the enzyme CYP2C9. Co-administration with CYP2C9 inhibitors may increase systemic exposure of Flurbiprofen.
  • Pharmacodynamic Effects: Flurbiprofen may reduce the natriuretic effect of diuretics through documented water and sodium retention.
  • Clearance Alteration: The product may cause an officially documented increase in the blood levels of both Methotrexate and Lithium due to reduced renal excretion.
  • Population Note: Caution is advised regarding interaction effects that lead to water and sodium retention in populations with pre-existing Severe Cardiac Dysfunction or Hypertension.

Regulatory documents define the product’s interaction structure primarily through its systemic NSAID effects, requiring caution with agents that alter its metabolism via CYP2C9 or share pharmacodynamic risk for the gastrointestinal and renal systems. The profile is further structured by documented constraints concerning the altered plasma concentrations of specific co-administered drugs.

Mechanism of Action

How Acustop Cataplasma Works

Acustop Cataplasma contains Flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID) that initiates interaction within defined biochemical pathways. The core of its mechanism involves targeted interference in peripheral inflammatory pathways, where the molecule accumulates selectively due to transdermal delivery.

Modulation of Eicosanoid Signaling Pathways

The mechanism of action involves interaction with biological targets within the eicosanoid pathway. Flurbiprofen functions as an inhibitor of the Cyclooxygenase (COX) enzyme, a key molecular step responsible for the conversion of arachidonic acid into pro-inflammatory mediators, primarily prostaglandins. This interaction modulates enzymatic activity, resulting in a measurable reduction in the localized synthesis of these mediators.

Downstream Physiological Consequence

By suppressing the production of prostaglandins, the drug modifies the early molecular steps that shape downstream physiological events. This reduction in localized mediator concentrations alters signal transduction within the affected peripheral pathways, which contributes to an observable adjustment of the body's physiological response at the site of application.

Dosage and Administration Information

How to Use Acustop Cataplasma

Acustop Cataplasma is a medicine containing the nonsteroidal anti-inflammatory drug (NSAID) flurbiprofen, provided as a soft, adhesive transdermal patch or plaster. The official instructions for use define a standardized approach for the application of this topical medicine, focusing on administration route, dosage, frequency, and placement constraints.


Official Administration Guidelines

Usage Parameter Standard Instruction
Route of Administration Topical application, restricted for external use on the skin.
Standard Dosing Schedule Apply one single patch to the designated affected area.
Application Frequency The Cataplasma is applied twice daily (B.I.D.), which establishes an application interval of approximately 12 hours.

Procedural and Population Constraints

The usage protocol specifies that the skin at the intended application site should be clean and dry before the patch is affixed. To maintain the integrity of the delivery system and avoid local complications, the patch must not be used on open wounds, damaged skin, or mucous membranes.

Regarding specific populations, official instructions place restrictions on pediatric use. The flurbiprofen cataplasma is not for use in children under 30 months of age. Use in children under 12 years requires consultation before application. These guidelines ensure the appropriate, standardized application of the 33 mg flurbiprofen dose, defining the necessary conditions for this temporary, localized treatment.

Recent Clinical Evidence

The research base for the flurbiprofen cataplasma, studied in adults, primarily involves conditions requiring localized management of discomfort.


Evidence for Use in Osteoarthritis

The core research structure consists of short-term Randomized Controlled Trials (RCTs) where the patch was compared against placebo or active topical treatments. Trials primarily research examined outcomes related to physical discomfort and daily functioning. Most high-quality research concentrated on the knee joint, meaning that the results apply only to the populations studied. Some prospective studies provide observational data on prolonged application for periods extending up to one year.


Evidence for Acute Musculoskeletal Injuries

Research exploring the use of the patch for conditions associated with acute or disruptive episodes, such as muscle strains, often relies on Systematic Reviews that explore the entire class of topical NSAID patches. These analyses data show patterns related to short-term pain relief. However, evidence is limited for isolated large-scale trials dedicated solely to the flurbiprofen formulation for every type of acute injury, and the typical follow-up durations were limited to the immediate recovery period.


Research Gaps and Areas of Uncertainty

Long-term effects are not fully established regarding the consistency of outcomes beyond the longest observational periods (52 weeks), particularly after use stops. Limited, specific trials examined the patch for postoperative pain in certain orthopedic patients, but the evidence gathered in this context is limited. Comparative evidence is lacking in broad, direct trials against non-topical pain management options, and data for certain groups remain insufficient.

Key Studies & References Flurbiprofen Patch (DailyMed) - Clinical and Regulatory Information

Frequently Asked Questions (FAQ)

Common questions about Acustop Cataplasma (FAQ)


Q: Does Acustop Cataplasma smell strongly?

A: According to official product information, the specific smell of the Acustop Cataplasma (flurbiprofen patch) is sometimes described as having a peculiar or characteristic odor due to its composition. This odor is typically related to the ingredients, such as L-menthol, which contribute to the patch's formulation.


Q: Is Acustop Cataplasma the same as a heating pad or a cooling patch?

A: No, Acustop Cataplasma is not the same as a heating pad or a general cooling patch. It is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) patch because it contains the active medicine flurbiprofen, which is delivered through the skin to the affected area. While some formulations may use a hydrogel that provides an initial cooling sensation, its main purpose is to deliver the anti-inflammatory drug, not just provide thermal relief.


Q: Can you reuse Acustop Cataplasma if it still feels sticky?

A: No, the official usage guidelines state that the Acustop Cataplasma patch is designed for single-use only. After the recommended application time, typically about 12 hours, the patch should be removed and discarded safely. Reusing the patch is not advised, as it is designed to deliver a specific amount of medicine during the single application period.


Q: Do I need a prescription for Acustop Cataplasma?

A: The regulatory classification for this flurbiprofen patch varies by brand and country. In some regions, the product may be identified in official databases as an Over-the-Counter (OTC) Human Drug, meaning it may be available without a doctor’s prescription. Check the specific product labeling in your country for confirmation.


Q: Can athletes use Acustop Cataplasma after a workout or injury?

A: Official product indications state that the medicine is used for the temporary relief of pain associated with common musculoskeletal issues such as sprains, strains, and sore muscles, which are frequent acute sports injuries. The patch is generally established for use in adults and adolescents over 12 years of age.


Q: Does Acustop Cataplasma stain clothing or sheets?

A: Hydrogel-based patches are often formulated to adhere well and be easily removable, with some manufacturers specifically stating the patch will not stain clothing. Following the proper application and removal guidelines may help limit residue.


Q: Is Acustop Cataplasma messy or hard to remove?

A: The cataplasma is formulated as a soft, flexible plaster with a hydrogel matrix designed for topical application. While the adhesive is strong enough for the patch to stay in place, it is designed to be removed completely. If the patch is difficult to remove, refer to the full usage instructions provided with the product.


Q: Does Acustop Cataplasma help with nerve pain or only muscle/joint pain?

A: According to regulatory documentation, the official indications for this NSAID patch include temporary relief from localized pain, including conditions such as Neuralgia, which is a type of nerve pain. The indications primarily focus on localized pain and inflammation in muscles, joints, and soft tissues.


Q: What part of the body is Acustop Cataplasma most often used on?

A: Official product information states that the patch is indicated for use on the affected body part for the temporary relief of pain and inflammation. This typically includes areas like the shoulder, back, joints, and other soft tissues where localized discomfort is present.


Q: Are there any warnings about using Acustop Cataplasma in hot weather?

A: Regulatory guidance suggests avoiding the use of the patch when sweating heavily (such as from heat or intense exercise), as this may interfere with how the medicine is absorbed and how well the patch adheres to the skin. For detailed storage requirements, refer to the storage section of the official product labeling.


Q: Can the adhesive in Acustop Cataplasma cause an allergic reaction?

A: Yes, official safety information states that hypersensitivity reactions, such as a localized rash or hives, can be caused by the active ingredient (flurbiprofen) or any of the inactive ingredients (excipients). If signs of an allergic reaction develop, use of the patch should be discontinued immediately, as advised in the official safety information.


Q: What should I do if Acustop Cataplasma falls off too quickly?

A: Application guidelines describe how to ensure the patch is firmly attached to the skin. If the patch falls off completely before the recommended time, it is for single use and should be disposed of safely. Application of a new patch should be done according to the recommended schedule.


Q: Is Acustop Cataplasma meant for acute injuries or long-term chronic pain?

A: Official studies and product information confirm that the patch is used for the temporary relief of pain and inflammation associated with both acute conditions (like sprains or strains) and chronic conditions (such as osteoarthritis). Official guidance emphasizes that appropriate use duration should be followed.


Q: Why would a doctor recommend Acustop Cataplasma over oral pain medication?

A: The topical route is designed to deliver the medication to the affected area for a localized therapeutic effect. This helps minimize systemic exposure compared to oral NSAIDs, potentially reducing the risk of systemic side effects affecting the gastrointestinal tract or cardiovascular system.


Q: Can Acustop Cataplasma be cut into smaller pieces for use on fingers or toes?

A: Official guidelines state that the patch should not be torn or cut. Cutting the patch can interfere with the controlled drug release and alter the dose intended for application.


Q: Is it true that Acustop Cataplasma uses plant extracts?

A: The active ingredient, flurbiprofen, is a synthetic NSAID. However, the patch's inactive ingredients (excipients) can include compounds that are naturally derived or synthesized, such as L-menthol or other aromatic ingredients. These components may be included for sensory effects or as part of the patch's delivery system.

How should Acustop Cataplasma be stored and disposed of?

How to Store and Dispose of Acustop Cataplasma

Official labeling requires Acustop Cataplasma (Piroxicam) to be stored at a controlled room temperature, generally below 30 C, to preserve its stability. The cataplasma must remain in its original foil pouch until the moment of use to protect it from light and moisture.

Once the foil pouch is opened, any unused product must be placed in a tightly closed container and used within a specific period, such as 4 weeks, as defined by regulatory stability data.

To ensure safety, the product must be kept out of the sight and reach of children.

Regarding disposal, all unused, expired, and used cataplasma patches must not be thrown into household trash or flushed down the toilet. Dispose of them only through a local drug take-back program or a facility designated for pharmaceutical waste, according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acustop Cataplasma found in:

A-Z Index: